Key facts
- This page summarizes Vishal Sikri's Form 4 filing for NEOGENOMICS INC (NEO).
- 3 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2024, 16:27.
Vishal Sikri - 23 Feb 2024 Form 4 Insider Report for NEOGENOMICS INC (NEO)
- Reporting relationship
- President Advanced Diagnostics
- Issuer ticker
- NEO
- Reported as of
- 23 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2024, 16:27:34 UTC
- Prior SEC filing
- 02 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ali Olivo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vishal Sikri filed Form 4 for NEOGENOMICS INC (NEO) on 27 Feb 2024.
Change
- Previous filing in this sequence was filed on 02 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NEO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 128,921
- Date
- 23 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NEO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +42,344
- Change %
- Price
- $0.000000
- Shares after
- 42,344
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,344
- Exercise price
- $16.45
- Footnotes
- F8
NEO
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +25,329
- Change %
- Price
- $0.000000
- Shares after
- 25,329
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,329
- Exercise price
- $0.000000
- Footnotes
- F6, F9
NEO
transaction
Derivative
Performance Stock Unit
Award
- Transaction value
- $0
- Shares
- +25,330
- Change %
- Price
- $0.000000
- Shares after
- 25,330
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,330
- Exercise price
- $0.000000
- Footnotes
- F6, F10
NEO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 319,112
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 319,112
- Exercise price
- $8.42
- Footnotes
- F2, F3
NEO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 39,683
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 39,683
- Exercise price
- $19.65
- Footnotes
- F4
NEO
holding
Derivative
Restricted Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 21,204
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,204
- Exercise price
- $0.000000
- Footnotes
- F5, F6
NEO
holding
Derivative
Performance Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 21,204
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,204
- Exercise price
- $0.000000
- Footnotes
- F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
This balance includes 1,205 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
Footnote F2
On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date.
Footnote F3
On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Footnote F4
On May 11, 2023, Mr. Sikri was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date.
Footnote F5
On May 11, 2023, Mr. Sikri was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
Footnote F6
Once vested, the shares of common stock are not subject to expiration.
Footnote F7
On May 11, 2023, Mr. Sikri was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
Footnote F8
On February 23, 2024, Mr. Sikri was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date.
Footnote F9
On February 23, 2024, Mr. Sikri was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
Footnote F10
On February 23, 2024, Mr. Sikri was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.